Independent Risk Factors for Ticagrelor-Induced Dyspnea in ACS Patients
Overview
This study identifies key risk factors for ticagrelor-induced dyspnea in patients with acute coronary syndrome (ACS). Higher peak concentrations of ticagrelor and lower levels of lactate dehydrogenase (LDH) and the metabolite ratio were associated with the development of dyspnea.
Background
Ticagrelor is a widely used P2Y12 receptor inhibitor in dual-antiplatelet therapy for ACS, but it is associated with a notable incidence of dyspnea. Understanding the risk factors for this adverse effect is essential for optimizing treatment strategies.
Data Highlights
Factor
Odds Ratio (OR)
P-value
LDH Levels
0.814 per 10 U/L
0.027
Ticagrelor Metabolite Ratio
0.523 per 0.1 increase
0.008
Peak Ticagrelor Concentration
1.173 per 100 ng/mL
0.012
Key Findings
23 out of 102 patients developed ticagrelor-induced dyspnea.
LDH levels were significantly lower in the dyspnea group (OR=0.814 per 10 U/L, P=0.027).
The ticagrelor metabolite ratio (AR-C124910XX/ticagrelor) was also lower in patients with dyspnea (OR=0.523 per 0.1 increase, P=0.008).
Peak ticagrelor concentration was higher in the dyspnea group (OR=1.173 per 100 ng/mL, P=0.012).
There was a negative correlation between peak ticagrelor concentration and LDH levels (r = -0.316, P = 0.001).
Clinical Implications
Clinicians should monitor LDH levels and ticagrelor metabolite ratios in patients receiving ticagrelor to identify those at higher risk for dyspnea. Adjusting treatment strategies based on these factors may enhance patient adherence and overall outcomes.
Conclusion
The study identifies plasma concentrations of ticagrelor, LDH levels, and the metabolite ratio as significant risk factors for ticagrelor-induced dyspnea in ACS patients.
